Moreover, both EPHX2 deficiency and sEH inhibition protected against AngII-induced cardiac hypertrophy, which was assessed by ratio of heart weight to body weight, left ventricular wall thickness (Table 2 and Table 3), relative cell area of cardiomyocytes and expression of the hypertrophy biomarker atrial natriuretic peptide (ANP) and β-isoform of myosin heavy chain (β-MHC) (Figure S1). Here, EPHX2 is linked to cardiac hypertrophy.